Share-based Payment Arrangement, Expense of Arbutus Biopharma Corp from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arbutus Biopharma Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Arbutus Biopharma Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,202,000, a 44% decline year-over-year.
  • Arbutus Biopharma Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,891,000, a 46% decline year-over-year.
  • Arbutus Biopharma Corp annual Share-based Payment Arrangement, Expense for 2024 was $8,986,000, a 3.4% decline from 2023.
  • Arbutus Biopharma Corp annual Share-based Payment Arrangement, Expense for 2023 was $9,301,000, a 30% increase from 2022.
  • Arbutus Biopharma Corp annual Share-based Payment Arrangement, Expense for 2022 was $7,182,000, a 12% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Arbutus Biopharma Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,891,000 $1,202,000 -$958,000 -44% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $5,849,000 $764,000 -$2,416,000 -76% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $8,265,000 $1,293,000 -$721,000 -36% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $8,986,000 $1,632,000 -$91,000 -5.3% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $9,077,000 $2,160,000 -$323,000 -13% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $9,400,000 $3,180,000 +$216,000 +7.3% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $9,184,000 $2,014,000 -$117,000 -5.5% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $9,301,000 $1,723,000 +$56,000 +3.4% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $9,245,000 $2,483,000 +$769,000 +45% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $8,476,000 $2,964,000 +$899,000 +44% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $7,577,000 $2,131,000 +$395,000 +23% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $7,182,000 $1,667,000 +$236,000 +16% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $6,946,000 $1,714,000 +$99,000 +6.1% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $6,847,000 $2,065,000 +$322,000 +18% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $6,525,000 $1,736,000 +$101,000 +6.2% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $6,424,000 $1,431,000 $0 0% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $6,424,000 $1,615,000 -$73,000 -4.3% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $6,497,000 $1,743,000 +$146,000 +9.1% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $6,351,000 $1,635,000 +$190,000 +13% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $6,161,000 $1,431,000 +$1,454,000 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q3 2020 $4,707,000 $1,688,000 +$172,000 +11% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $4,535,000 $1,597,000 -$2,187,000 -58% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $6,722,000 $1,445,000 -$77,000 -5.1% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $6,799,000 $23,000 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q3 2019 $1,516,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $3,784,000 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $1,522,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1

Arbutus Biopharma Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,986,000 -$315,000 -3.4% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $9,301,000 +$2,119,000 +30% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $7,182,000 +$758,000 +12% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $6,424,000 +$263,000 +4.3% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $6,161,000 -$638,000 -9.4% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
2019 $6,799,000 +$792,000 +13% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
2018 $6,007,000 -$9,110,000 -60% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
2017 $15,117,000 -$24,042,000 -61% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
2016 $39,159,000 +$17,066,000 +77% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018 2017 FY
2015 $22,093,000 +$18,810,000 +573% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018 2017 FY
2014 $3,283,000 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.